Technical Analysis for BNTC - Benitec Biopharma Limited

Grade Last Price % Change Price Change
C 5.12 -0.19% -0.01
BNTC closed up 3.43 percent on Wednesday, March 27, 2024, on 24 percent of normal volume.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish -0.19%
Gapped Up Strength -0.19%
20 DMA Resistance Bearish 3.23%
Spinning Top Other 3.23%
Gapped Up Strength 3.23%
20 DMA Resistance Bearish 3.23%
1,2,3 Pullback Bullish Bullish Swing Setup 3.23%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 3.23%
Inside Day Range Contraction 3.23%
Fell Below 20 DMA Bearish 3.43%

   Recent Intraday Alerts

Alert Time
20 DMA Support about 3 hours ago
10 DMA Support about 3 hours ago
Fell Below Previous Day's Low about 3 hours ago
Down 1% about 3 hours ago
Up 2% about 3 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Benitec Biopharma Limited Description

Benitec Biopharma Limited, a biotechnology company, develops novel treatments for chronic and life-threatening conditions based on its gene silencing technology, DNA-directed RNA interference (ddRNAi). The company's ddRNAi technology provides novel therapeutics to treat a range of human medical diseases and conditions, such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer, and oculopharyngeal muscular dystrophy (OPMD). Its pipeline of in-house and partnered therapeutic programs include TT-034 for hepatitis C; Tribetarna for the treatment of chemotherapy resistant non-small cell lung cancer; Hepbarna for Hepatitis B; and Pabparna for the treatment of OPMD. The company also licenses its ddRNAi technology to biopharmaceutical companies for the clinical applications comprising HIV/AIDS, retinitis pigmentosa, and Huntington's disease. Benitec Biopharma Limited was founded in 1997 and is based in Sydney, Australia.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Biopharmaceutical Biology Pain Genetics Chemotherapy Small Cell Lung Cancer Genetic Engineering Hepatitis B Macular Degeneration Gene Expression Dystrophy Muscular Dystrophy Hepatitis C Huntington's Disease Wet Age Related Macular Degeneration HIV/Aids RNA Clinical Applications Retinitis Rna Interference Ai Technology Gene Silencing Retinitis Pigmentosa Chronic And Life Threatening Conditions Oculopharyngeal Muscular Dystrophy

Is BNTC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 9.01
52 Week Low 1.86
Average Volume 16,626
200-Day Moving Average 3.45
50-Day Moving Average 3.91
20-Day Moving Average 5.08
10-Day Moving Average 5.09
Average True Range 0.34
RSI (14) 60.78
ADX 45.33
+DI 31.21
-DI 12.30
Chandelier Exit (Long, 3 ATRs) 4.92
Chandelier Exit (Short, 3 ATRs) 5.21
Upper Bollinger Bands 5.47
Lower Bollinger Band 4.69
Percent B (%b) 0.56
BandWidth 15.42
MACD Line 0.31
MACD Signal Line 0.39
MACD Histogram -0.0797
Fundamentals Value
Market Cap 13.2 Million
Num Shares 2.57 Million
EPS -234.82
Price-to-Earnings (P/E) Ratio -0.02
Price-to-Sales 98.27
Price-to-Book 0.33
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.42
Resistance 3 (R3) 5.43 5.35 5.37
Resistance 2 (R2) 5.35 5.28 5.34 5.35
Resistance 1 (R1) 5.24 5.23 5.30 5.23 5.34
Pivot Point 5.16 5.16 5.19 5.15 5.16
Support 1 (S1) 5.05 5.09 5.11 5.04 4.92
Support 2 (S2) 4.97 5.04 4.96 4.91
Support 3 (S3) 4.86 4.97 4.89
Support 4 (S4) 4.85